Rapid and robust preclinical and clinical development of CAR T-cell therapies

A mid-sized biotech sponsor developing novel autologous and allogeneic CAR T therapies engaged Labcorp to support several solid tumor and hematologic malignancy therapeutic programs. The goal was to help the sponsor identify lead assets, successfully navigate through investigational new drug (IND) submission and conduct Phase I/II dosing studies, all against an aggressive timeline. The sponsor also sought to replace a spreadsheet-based system for tracking patient recruitment and site performance with a more advanced technology solution featuring real-time capabilities. The project involved coordination across multiple Labcorp business solutions for a streamlined effort including preclinical pharmacology, toxicology, clinical development and laboratory services.